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S OMATOSTATIN is involved in the negative control of the normal function of a number of organ systems. 
One might call the peptide an inhibitory tissue (growth) 
factor, which mainly prevents local overreaction from a 
multitude of stimulatory factors. Long-term administration 
of somatostatin analogs in most instances only transiently 
inhibits physiological ctions, either because of their desen- 
sitizing effects, or because of the compensatory reaction of 
local stimulatory factors which in most instances eventually 
have an overriding action. After administration of octreo- 
tide for 1 week, its stimulatory effect on intragastric pH is 
lost, while similarly, its inhibitory effects on pancreatic 
amylase, trypsin, and lipase secretion decrease consider- 
ably. Also, octreotide acutely blunts thyrotropin-releasing 
hormone (TRH)-stimulated thyrotropin (TSH) release, but 
long-term therapy does not affect thyroid function, prob- 
ably because of local adaptation by other regulatory factors. 
However, this is not always the case, as long-term octreo- 
tide therapy relentlessly diminishes gallbladder contrac- 
tion. 
These considerations have consequences for the clinical 
use of somatostatin analogs. On the one hand, it makes 
them safe drugs with few side effects; most initial symptoms 
such as nausea, cramps, diarrhea, and fatty stools disappear 
spontaneously within 2 to 3 weeks as a consequence of local 
adaptation in the gastrointestinal tract and exocrine pan- 
creas. Only gallstone formation is a long-term problem, 
although clinically symptomatic gallbladder disease occurs 
in about 1% of individuals per treatment year on octreo- 
tide. On the other hand, these mechanisms of local adapta- 
tion probably explain why the inhibitory effects of octreo- 
tide in functional gastrointestinal diseases (upper 
gastrointestinal bleeding, pancreatitis, diarrhea, and pancre- 
atic fistula output) are only transient and rather short-lived, 
limiting the efficacy of the drug in these diseases. 
Will it be possible to improve the efficacy of somatostatin 
analogs in the treatment of functional gastrointestinal 
diseases? There is little evidence that intermittent low-dose 
octreotide might prevent desensitization of somatostatin 
receptors or delay local adaptation. The use of the long- 
acting depot preparation of octreotide, which induces 
constant high circulating levels of the peptide for many 
weeks, will give an answer to these questions. Also, there is 
at present little evidence that somatostatin receptor subtype- 
specific analogs with a profile different from octreotide, 
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such as BIM 23014 or RC-160, might improve the long-term 
effectiveness oftherapy for bleeding, diarrhea, pancreatitis, 
or fistula output. Most studies so far suggest hat the 
continuous infusion of somatostatin-14 has similar effects 
to octreotide on normal gastrointestinal function. However, 
with regard to the effect on insulin secretion, there might be 
an important difference. Octreotide was originally demon- 
strated, in monkeys, to inhibit growth hormone (GH) 45 
times more potently than natural somatostatin, but insulin 
only 1.3 times more potently. Recently, it was demonstrated 
that the inhibitory actions of somatostatin on GH and 
insulin release are mediated by different somatostatin 
receptor subtypes. This selective ffect of octreotide, which 
inhibits normal insulin release only transiently, has contrib- 
uted to its minor effects on carbohydrate tolerance in 
humans. This also suggests that somatostatin receptor 
subtype-specific analogs with a different profile might 
cause hyperglycemia, limiting their day to day use in 
gastroenterology. The same limitation would apply to 
long-acting somatostatin analogs, which activate all recep- 
tor subtypes to a similar extent o natural somatostatin. 
Octreotide does not cross the blood-brain barrier in 
humans. This limits its investigational use in brain disorders 
in which somatostatin regulation disturbances have been 
demonstrated. Nonpeptide somatostatin analogs that cross 
the blood-brain barrier emain to be developed. 
The most successful se of (long-acting) octreotide so far 
is in the treatment of acromegaly. Effective control of GH 
secretion by the pituitary tumor and subsequent ormaliza- 
tion of insulin-like growth factor-1 (IGF-1) and insulin-like 
growth factor-binding protein 3 (IGFBP-3) levels occurs in 
the majority of patients. Elderly patients with small pitu- 
itary tumors are especially sensitive to octreotide. There- 
fore, octreotide has been proposed as a primary therapy in 
the treatment of elderly acromegalic patients. An impor- 
tant observation is that no loss of action, escape, or 
desensitization f somatostatin receptors eems to occur in 
the pituitary tumors of acromegalics, even after more than 
10 years of therapy on 3 x 100 p.g octreotide (in total 
>10,000 injections). This suggests a difference in the 
turnover, in the degree of internalization, and/or in the 
recruitment of the somatostatin receptors to the tumor cell 
membrane in human pituitary tumors, compared with the 
target cells of the normal gastrointestinal tract and the 
pancreas. 
Somatostatin analogs are currently used with consider- 
able success in the treatment of hormonal hypersecretion f 
metastasized carcinoids and islet cell tumors. Clinical 
improvement during octreotide therapy is mainly mediated 
via a direct inhibitory effect on hormone production by the 
tumor, but indirect non-tumor-mediated effects on intesti- 
nal fluid production and/or intestinal contractility also 
contribute to the subjective well-being of many patients. 
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Somatostatin analogs thus contribute to the quality of life of 
patients with this type of metastasized endocrine tumor. 
However, surgery remains the primary treatment in such 
patients. Somatostatin receptor visualization of most tu- 
mors optimalizes the staging of these diseases and radiogu- 
ided surgery assists in improving the outcome of surgical 
intervention. 
Shrinkage of tumor (metastases) during octreotide 
therapy has been reported in 10% to 20% of carcinoid and 
vasoactive intestinal polypeptide (VIP)-oma patients, but 
this shrinkage is temporary and transient. Control of tumor 
growth occurs in about half of the patients for a period of 8 
to 16 months, but eventually all patients escape from 
somatostatin analog therapy with regard both to hormonal 
hypersecretion and to tumor growth. It is not evident at 
present whether this escape is the consequence of desensiti- 
zation, structural changes in the somatostatin receptors on 
these tumors, the selection of rapidly growing clones of 
dedifferentiated tumor cells lacking these receptors, or a 
mixture of these phenomena. Somatostatin receptor scintig- 
raphy can be used to find answers to this. The four main 
questions concerning the use of somatostatin analogs in 
gastroenteropancreatic tumors are as follows: 
(1) which mechanism(s) are responsible for the loss of 
efficacy of octreotide in the control of hormonal 
hypersecretion a d tumor growth; 
(2) is it possible to control tumor growth with radio- 
therapy with radionuclide-coupled somatostatin ana- 
logs, and if so, at what stage should this procedure be 
performed; 
(3) at what stage should chemotherapy and/or chemoem- 
bolization of liver metastases be considered, espe- 
cially with regard to the points raised under 1 and 2; 
and 
(4) is there a place for novel somatostatin receptor 
subtype-specific analogs? 
Recent evidence suggests that most, if not all, antihor- 
monal and antimitotic actions of somatostatin are mediated 
via receptor subtypes 2 and 5, making octreotide, BIM 
23014, and RC-160 the most optimal analogs in the treat- 
ment of carcinoids and most islet ceil tumors. Only in the 
case of insulinomas i there evidence that receptor subtypes 
are present hat do not or only minimally bind octreotide 
and RC-160. For such tumors, the development of analogs 
with an alternative binding profile is of some importance. 
Somatostatin analogs inhibit the growth of a variety of 
tumors in different animal models. Somatostatin receptors 
have been found on many human breast, thyroid, prostatic, 
and other adenocarcinomas, on brain tumors such as 
meningiomas, and on hematological malignancies. 
What are the consequences for practical oncology? Little 
is known at present concerning the potential value of 
(high-dose?) octreotide therapy in patients with inoperable 
neuroendocrine tumors, breast cancer, malignant lympho- 
mas, and meningiomas. Octreotide directly inhibits hor- 
mone release and cell growth in most cultured human 
neuroendocrine tumors, but a different effect was observed 
in cultured human meningiomas; octreotide inhibited ad- 
enylyl cyclase activity in these tumor cells, but stimulated 
their growth. Octreotide probably interferes with the inhibi- 
tory autocrine growth control of meningioma cells. Despite 
the direct antimitotic effects of somatostatin analogs on 
(monoclonal) breast cancer cell lines, the nonhomogeneous 
distribution of somatostatin receptors in many human 
breast cancer specimens uggests that treatment with so- 
matostatin analogs might only affect parts of these tumors. 
The differential antimitotic and antihormonal effects of 
natural somatostatin, octreotide, and RC-160, the variable 
presence of different somatostatin receptor subtypes on 
different human tumor types, as well as the as yet undefined 
pathophysiological significance of the presence of somato- 
statin receptors on tumor vascularization, have to be 
investigated further. These considerations mean that a 
place for somatostatin analog treatment in patients with 
inoperable somatostatin receptor,positive cancer is not 
established yet. However, there seems little doubt that 
somatostatin receptor scintigraphy can enhance the quality 
of clinical trials of somatostatin analogs by selecting those 
patients whose tumors express omatostatin receptors. In 
this regard it seems important that the direct antiproiifera- 
tive action of octreotide on cultured tumor cells is additive 
to that exerted by different cytostatic drugs. 
The main questions in the field of oncology, which need 
to be addressed further are as follows: 
(1) what is the biological significance of the heteroge- 
neous distribution of somatostatin receptors on ad- 
cnocarcinomas? 
(2) Does somatostatin analog therapy result in the selec- 
tion of preferentially growing somatostatin receptor- 
negative tumor cells? 
(3) Is it possible to induce, using somatostatin a alogs, a
consistent lowering of IGF-1 bioactivity in the circu- 
lation, as well as that of other hormones that have 
been implicated in tumour growth? 
(4) Which human cancers are controlled by their intracel- 
lular cyclic adenosine monophosphate (cAMP) lev- 
els? Is somatostatin analog therapy, which inhibits 
the adenylate cyclase activity of such tumor cells, 
risky and contraindicated? 
A number of small peptides have been identified, which 
are widely distributed over the human body, and are potent 
and important regulators of biological processes in normal 
tissues, as well as in the growth of certain cancers (eg, 
bombesin, substance P, vasoactive intestinal polypeptide 
[VIP], cholecystokinin, and gastrin). The recent develop- 
ment of somatostatin analogs for the diagnosis and treat- 
ment of a variety Of cancers will be repeated in the near 
future with other small peptides and their analogs. Despite 
the broad range of physiological ctions of somatostatin, its
analogs control hormonal hypersecretion by endocrine 
tumors that express receptor s for this peptide or analog 
without important side effects. As mentioned earlier, the 
high density of somatostatin receptors on tumors (and on 
groups of activated immune cells), as well as the availability 
of potent and stable somatostatin analogs as radioligands, 
made it possible to develop an in vivo technique for ttieir 
visualization. Somatostatin receptor scintigraphy repre- 
sents the first example of tile clinical use of a small peptide 
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as an efficient in vivo diagnostic tool for the presence of 
peptide receptors. Apart from its localizing merits, a 
positive scan often predicts a favorable response to octreo- 
tide therapy. Recently, VIP receptor scintigraphy and 
substance P receptor scintigraphy have been successfully 
developed for the visualization of gastrointestinal cancer, as 
well as chronic immune diseases. Small peptides such as 
somatostatin may be considered a powerful alternative to 
monoclonal antibodies and their fragments. 
Radiolabeled chelated somatostatin analogs are already 
more than a theoretical option. However, there is consider- 
able variability in uptake of radioactivity between tumors. 
Experimental studies show that it might be possible to 
transiently upregulate somatostatin receptor expression, 
increasing their uptake of radioactivity, Radiotherapy with 
radionuclide-coupled stable somatostatin analogs is the 
most promising use of these compounds in palliative oncol- 
ogy. 
